Mechanistically, m6A mRNA modification affects the YTHDF1-dependent translation enhancement of the negative AKT regulator PHLPP2 and YTHDF2-dependent destabilization of the mRNAs of positive AKT regulators PRR5, PRR5L, and mTOR. Thus, either METTL14 mutation or decreased METTL3 expression leads to m6A reduction in these target mRNAs and, as a result, promotes cell proliferation and tumorigenicity of endometrial cancer through AKT activation96. Here, AKT1 is linked to endometrial cancer.